Angelica Welch

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

Manuel Hidalgo, MD, PhD, discusses the potential with BL-8040 and pembrolizumab in pancreatic adenocarcinoma.

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

The potent FGFR1-3 inhibitor pemigatinib showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma.

Sameek Roychowdhury, MD, PhD, discusses the potential for FGFR inhibitors in the treatment of patients with cholangiocarcinoma who harbor FGFR fusions.

The selective pan-FGFR kinase inhibitor infigratinib showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma who harbor FGFR2 fusions.

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Pascal Hammel, MD, PhD, discusses the potential for eryaspase, and the future direction of the pancreatic cancer landscape.

Michael J. Pishvaian, MD, PhD, discusses the impact of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.

Valerie Sugiyama, MD, discusses the treatment of patients with recurrent ovarian cancer.

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.

Briana Patterson, MD, discusses the off-target effects of tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Barbara A. Burtness, MD, discusses the impact that the KEYNOTE-048 data could have on the treatment of patients with head and neck squamous cell carcinoma.

Benjamin P. Levy, MD, discusses optimal strategies for molecular interrogation of non–small cell lung cancer.

Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.

Favorable neurocognitive outcomes were observed in pediatric patients with brain tumors with the use of proton radiation therapy compared with X-ray radiation therapy.

Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer.

Diana P. English, MD, discusses the promise for ADCs in the landscape of ovarian cancer treatment and targeting p53 mutations in patients with ovarian cancer.

Mark Emberton, MD, FRCS, discusses updates in the diagnosis and treatment of patients with localized prostate cancer.

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.